Neoparin Multi (Enoxaparin Sodium)

Enoxaparin Sodium, the active ingredient in Neoparin Multi, is a low molecular weight heparin presented as an injectable solution for subcutaneous, intravenous or extracorporeal administration. It is used to prevent and treat venous thromboembolic disorders in at‑risk patients.

GNH USA supplies Neoparin Multi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution. Customers benefit from reliable lead times, secure packaging, and dedicated technical support throughout the supply chain.

Neoparin Multi, a low molecular weight heparin, is employed in the prevention and treatment of venous thromboembolism. - Surgical patients at risk of deep vein thrombosis (DVT): prevents clot formation during and after surgery. - Patients with acute DVT: facilitates clot resolution and reduces propagation. - Individuals with pulmonary embolism (PE): treats existing emboli and lowers recurrence risk. - Medically ill hospitalized patients: provides prophylaxis against thromboembolic events.

Adverse reactions to Enoxaparin Sodium may vary in frequency and severity.

Common Side Effects: - Injection site pain or erythema: mild discomfort at the administration site. - Minor bleeding or bruising: occasional superficial hemorrhage. - Nausea or headache: transient gastrointestinal or neurologic symptoms.

Serious or Rare Side Effects: - Major bleeding: life‑threatening hemorrhage requiring medical intervention. - Heparin‑induced thrombocytopenia (HIT): immune‑mediated platelet drop with paradoxical clotting. - Allergic reactions: urticaria, angioedema, or anaphylaxis. - Spinal or epidural hematoma: bleeding in the central nervous system after neuraxial procedures. - Severe skin necrosis: localized tissue death at injection sites. - Paradoxical thrombosis: clot formation despite anticoagulation.

When using Enoxaparin Sodium, clinicians should consider several safety measures. - Renal impairment: adjust dose or monitor anti‑Xa levels closely. - Elderly patients: increased bleeding risk; use the lowest effective dose. - Concurrent anticoagulants: avoid unless clinically justified to prevent additive effects. - History of HIT: contraindicated due to risk of severe thrombocytopenia. - Surgery or invasive procedures: discontinue prior to the procedure as recommended. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Enoxaparin Sodium can interact with other medicines, altering its anticoagulant effect.

Major Interactions (Avoid): - Concurrent use with unfractionated heparin: additive anticoagulant effect, high bleeding risk. - Combination with warfarin during initial therapy: increased INR and bleeding. - Use with potent antiplatelet agents (e.g., clopidogrel, high‑dose aspirin): severe hemorrhage. - Concomitant thrombolytics (e.g., alteplase): excessive bleeding.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase minor bleeding. - Selective serotonin reuptake inhibitors (SSRIs): modestly raise bleeding tendency. - Renal‑clearing drugs (e.g., aminoglycosides): may affect drug clearance. - Contrast media used in imaging: monitor coagulation parameters.